Want to see GB:AZN full AI Analyst Report?
AZN Stock Chart & Stats
12670.00 p
268.00 p(2.12%)
At close: 4:00 PM EDT
12670.00 p
268.00 p(2.12%)
Day’s Range― - ―
52-Week Range9,892.00 p - 15,554.00 p
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.55M
Market Cap
£195.91B
Enterprise Value240.56K
Total Cash (Recent Filing)£4.99B
Total Debt (Recent Filing)£32.41B
Price to Earnings (P/E)25.3
Beta1.16
Next Earnings
Oct 30, 2026EPS Estimate
1.96Next Dividend Ex-DateN/A
Dividend Yield1.87%
Share Statistics
EPS (TTM)6.72
Shares Outstanding1,551,024,500
10 Day Avg. Volume2,495,494
30 Day Avg. Volume2,545,492
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£16,093.33Price Target Upside27.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)10.25
Revenue Forecast (FY)£63.34B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained high gross and net margins indicate durable pricing power and efficient operations across core franchises. Strong operating leverage supports reinvestment in R&D and launches, allowing the company to fund growth and absorb pricing/regulatory pressure over the medium term.
Robust Cash GenerationConsistent positive operating and free cash flow provides structural capacity to fund capital expenditure, sustain R&D investment, pay dividends and service debt. Over 2–6 months this cash generation underpins strategic optionality and buffer versus transient revenue swings.
Large Late‑stage Pipeline & Oncology LeadershipA deep late‑stage pipeline and clear oncology momentum create durable growth optionality beyond products facing LOE. Multiple pivotal readouts and recent NMEs expand addressable markets and support high‑margin future sales, reducing single‑product dependency over the medium term.
Bears Say
Elevated Net Debt & Rising LeverageSizeable debt and a recent increase in net debt reduce financial flexibility and raise interest‑rate sensitivity. If earnings momentum weakens or R&D/capex needs stay high, leverage could constrain M&A, share buybacks or capital allocation decisions over the coming months.
Loss‑of‑exclusivity PressuresPatent expiries and generic/biosimilar entry are structural revenue headwinds for mature products. Sustained LOE-driven declines require timely replacements from launches and pipeline; failure to offset these losses would compress revenue mix and margin profile over the medium term.
Clinical & Execution Risk From Phase III FailuresLate‑stage trial failures materially reduce expected peak sales and can invalidate development investments. Recurrent Phase III setbacks increase regulatory uncertainty and raise the probability that some pipeline assets will not deliver expected replacements for LOE products.
AstraZeneca News
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9892.00 p and its highest was 15554.00 p in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £195.91B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Oct 30, 2026 which is in 85 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 27, 2026. The company reported 1.955 p earnings per share for the quarter, beating the consensus estimate of 1.84 p by 0.114 p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Semiannually dividend of 159.5 p which represents an annual dividend yield of 1.87%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 1.96.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,551,024,500 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.955 p in its last earnings report, beating expectations of 1.84 p. Following the earnings report the stock price went up 1.721%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£16,093.33 (27.02% Upside)
£16,093.33 (27.02% Upside)
Blogger Sentiment
Bullish
GB:AZN Sentiment 63%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 45%
Bearish news 55%
Bearish news 55%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.19%
12-Months-Change
Fundamentals
Return on Equity
1.87%
Trailing 12-Months
Asset Growth
6.38%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
AZN Stock 12 Month Forecast
Average Price Target
16,093.33 p
▲(27.02% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―